JCA Reports & Regulatory Divergence

MarcusWelcome to Access Brief, the daily AI podcast on HEOR, HTA, and market access. I'm Marcus, with Sara. Today: Tovorafenib JCA report, Mirvetuximab CDF, D-VRd NICE reversal, and Avacopan regulatory crisis. Let's get into it.

MarcusThe second JCA report for tovorafenib is out. Procedural timeline implications are clear—HTA bodies are now prioritizing real-world evidence integration earlier in assessments. This signals a shift toward adaptive evidence frameworks but creates uncertainty for sponsors with mature data packages. The report emphasizes methodological consistency across oncology submissions.

SaraConsistency is the word, but I question the operational reality. HTA bodies are increasingly demanding RWE before pivotal trials even conclude. This creates resource strain for biotech companies with limited infrastructure. The focus on procedural timelines overlooks the fact that most sponsors lack federated network capabilities to generate timely RWE. We're creating a two-tier system where only well-resourced players can comply.

MarcusResource constraints are real, but the alternative is delaying assessments. The JCA scale-up to 50 assessments demonstrates the need for efficiency gains. Federated networks aren't mandatory—suppliers can leverage existing databases. The procedural clarity benefits the entire ecosystem by reducing assessment variability.

SaraEfficiency shouldn't come at the cost of evidence rigor. The interim CDF recommendation for mirvetuximab soravtansine shows HTA bodies accepting surrogate endpoints in ADCs, but this sets a dangerous precedent. Oncology portfolios are becoming increasingly complex, and surrogate endpoints don't always translate to real-world benefits. We're risking coverage decisions based on biomarkers that may not capture clinical value.

MarcusADCs present unique challenges with their targeted mechanisms. The CDF approach acknowledges that traditional endpoints may not capture their full impact. The recommendation includes stringent pharmacovigilance requirements to mitigate risks. This is a pragmatic adaptation to evolving therapeutic paradigms.

SaraPragmatism is different from lowering standards. The D-VRd NICE reversal demonstrates the consequences of over-reliance on minimal residual disease endpoints. MRD is a powerful prognostic tool but lacks established cost-effectiveness thresholds. NICE's reversal highlights how surrogate endpoints can lead to unstable reimbursement decisions when real-world data doesn't align with trial expectations.

MarcusThe reversal underscores the need for adaptive HTA frameworks. NICE is now incorporating long-term follow-up data into their assessments, which is appropriate for novel mechanisms. The focus should be on developing robust methodologies for surrogate endpoints rather than rejecting them outright.

SaraDeveloping methodologies takes years. In the interim, we're left with inconsistent coverage. Avacopan's cross-jurisdictional regulatory crisis exemplifies how divergent safety assessments create HEOR chaos. EMA and FDA have conflicting signals on renal risk, forcing sponsors to develop separate dossiers. This doubles HEOR resource requirements and fragments patient access.

MarcusRegulatory divergence isn't new, but the pace of divergence is accelerating. The Avacopan case highlights the need for harmonized pharmacovigilance standards. HEOR teams must now build contingency plans for regulatory splits, which complicates value demonstration strategies globally.

SaraContingency plans are reactive solutions. The root cause is the absence of global regulatory alignment. Until we address that, HEOR teams will continue to operate in silos, duplicating efforts and creating inconsistent value narratives. This isn't sustainable for complex therapies with global reach.

MarcusThe challenges are significant, but the JCA scale-up and CDF adaptations show progress. The key is developing flexible evidence strategies that accommodate regulatory variability. Back tomorrow on Access Brief. Show notes at outcomes-analytica.no.